Pricing Availability   Qty
Description: Highly potent active component of ADNP; prevents amyloid β aggregation; active in vivo
Alternative Names: AL-108,NAP (peptide),NAPVSIPQ
Purity: ≥95% (HPLC)
Literature (1)

Biological Activity for Davunetide

Davunetide is a highly potent active component of activity-dependent neuroprotective protein (ADNP). Prevents β-amyloid aggregation. Reduces hyperphosphorylated tau levels and increases tau-microtubule interactions; neuroprotective at femtomolar concentrations in vitro. Exerts neuroprotective effects in schizophrenia models associated with microtubule-autophagy insufficiency in MAP6-deficient mice. Modulates HIFs and VEGF expression and suppresses retinal cell apoptosis in an in vivo diabetic retinopathy model.

Technical Data for Davunetide

M. Wt 824.93
Formula C36H60N10O12
Storage Store at -20°C
Purity ≥95% (HPLC)
CAS Number 211439-12-2
PubChem ID 9832404
Smiles O=C(N[C@@H](C)C(N1[C@@H](CCC1)C(N[C@@H](C(C)C)C(N[C@@H](CO)C(N[C@@H]([C@@H](C)CC)C(N2[C@@H](CCC2)C(N[C@@H](CCC(N)=O)C(O)=O)=O)=O)=O)=O)=O)=O)[C@H](CC(N)=O)N

The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.

Tocris products are intended for laboratory research use only, unless stated otherwise.

Solubility Data for Davunetide

Solubility Soluble to 1 mg/ml in water

Product Datasheets for Davunetide

Certificate of Analysis / Product Datasheet
Select another batch:

References for Davunetide

References are publications that support the biological activity of the product.

Bassan et al (1999) Complete sequence of a novel protein containing a femtomolar-activity-dependent neuroprotective peptide. J.Neurochem. 72 1283 PMID: 10037502

Gozes et al (2000) Activity-dependent neurotrophic factor: intranasal administration of femtomolar-acting peptides improve performance in a water maze J.Pharmacol.Exp.Ther. 293 1091 PMID: 10869414

Sragovich et al (2017) ADNP Plays a Key Role in Autophagy: From Autism to Schizophrenia and Alzheimer's Disease. Bioessays 39 doi: 10.1002 PMID: 28940660

Melo et al (2017) Impairment of mitochondria dynamics by human A53T α-synuclein and rescue by NAP (davunetide) in a cell model for Parkinson's disease. Exp.Brain Res. 235 731 PMID: 27866262

D'Amico et al (2018) NAP counteracts hyperglycemia/hypoxia induced retinal pigment epithelial barrier breakdown through modulation of HIFs and VEGF expression. J.Cell Physiol. 233 1120 PMID: 28436035

Ivashko-Pachima et al (2017) ADNP/NAP dramatically increase microtubule end-binding protein-Tau interaction: a novel avenue for protection against tauopathy. Mol Psychiatry 22 1335 PMID: 28115743

If you know of a relevant reference for Davunetide, please let us know.

View Related Products by Target

View Related Products by Product Action

View all Amyloid β Peptide Inhibitors

Keywords: Davunetide, Davunetide supplier, AL-108, NAP, (peptide), NAPVSIPQ, Amyloid, Beta, Peptides, Microtubules, 6779, Tocris Bioscience

Citations for Davunetide

Citations are publications that use Tocris products.

Currently there are no citations for Davunetide. Do you know of a great paper that uses Davunetide from Tocris? Please let us know.

Reviews for Davunetide

There are currently no reviews for this product. Be the first to review Davunetide and earn rewards!

Have you used Davunetide?

Submit a review and receive an Amazon gift card.

$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image

$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image

$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image

Submit a Review

Literature in this Area

Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!

*Please note that Tocris will only send literature to established scientific business / institute addresses.

Alzheimer's Disease Poster

Alzheimer's Disease Poster

Alzheimer's disease (AD) is a debilitating and progressive neurodegenerative disease and the most common cause of dementia, affecting approximately 30% of individuals aged over 85 years. This poster summarizes the cellular and molecular mechanisms of AD.